Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Summary

This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.

Timeline

Start

2008-10

Primary completion

2011-01

Completion

2012-04

Publications

• Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247.

Drugs

Indications